Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will participate in a fireside chat with Harvey Briggs, Chief Communications Officer, Force Family Office. Joining them will be James Cardia, Ph.D., who will explore siRNA therapy and skin cancer treatments.

"We are excited to take part in this fireside chat with Force Family Office," said Robert Bitterman, CEO and Chairman of Phio Pharmaceuticals. "Dr. Jim Cardia will discuss the future direction of siRNA oncology and highlight how our INTASYL® siRNA program represents a differentiated and innovative approach to immuno-oncology."